Findings

What do systematic reviews say?

873 questions · 883 findings · 38 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 319 · 36.1%GRADE not reported 18 · 2%Very low 198 · 22.4%Low 186 · 21.1%Moderate 147 · 16.6%High 15 · 1.7%

Summary of findings ‐ high‐dose azithromycin vs low‐dose azithromycin

Pulmonary exacerbations · children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 47 participants
Very low

Summary of findings: water‐soluble vitamin E vs control

Vitamin E total lipid ratio · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Vitamin E supplementation in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: water‐soluble vitamin E vs control

Vitamin E levels in serum: umol/L · adults and children with cystic fibrosis

Summary of findings: water‐soluble vitamin E may leads to higher vitamin E levels in serum: umol/L compared with control (low certainty).

1 finding from 1 review

Vitamin E supplementation in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
MD 19.74 [13.48, 26]
1 study · 45 participants
Low

Summary of findings: water‐soluble vitamin E vs control

Neuropathy due to vitamin E deficiency · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Vitamin E supplementation in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: water‐soluble vitamin E vs control

Retinopathy due to vitamin E deficiency · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Vitamin E supplementation in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: water‐soluble vitamin E vs control

Body‐mass index (BMI) · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Vitamin E supplementation in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: water‐soluble vitamin E vs control

Height (cm) · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Vitamin E supplementation in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: water‐soluble vitamin E vs control

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Vitamin E supplementation in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Inhaled corticosteroids vs placebo

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Inhaled corticosteroids for cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 250 participants
Low

Inhaled corticosteroids vs placebo

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Inhaled corticosteroids for cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 250 participants
Low

Inhaled corticosteroids vs placebo

BHR: change in PC20 values · adults and children with cystic fibrosis

1 finding from 1 review

Inhaled corticosteroids for cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 100 participants
Very low

Inhaled corticosteroids vs placebo

Change in exercise tolerance · adults and children with cystic fibrosis

1 finding from 1 review

Inhaled corticosteroids for cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low

Inhaled corticosteroids vs placebo

Respiratory exacerbations: number of days on intravenous antibiotics for respiratory exacerbations · adults and children with cystic fibrosis

It is very uncertain whether summary of findings: inhaled corticosteroids changes respiratory exacerbations: number of days on intravenous antibiotics… compared with placebo (very low certainty).

1 finding from 1 review

Inhaled corticosteroids for cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 17 participants
Very low

Inhaled corticosteroids vs placebo

Quality of life: Quality of Well Being score change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Inhaled corticosteroids for cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Low

Inhaled corticosteroids vs placebo

Adverse effects · adults and children with cystic fibrosis

1 finding from 1 review

Inhaled corticosteroids for cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 295 participants
Low

Summary of findings ‐ monotherapy: lumacaftor vs placebo

Survival · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 147 participants
Low

Summary of findings ‐ monotherapy: lumacaftor vs placebo

Quality of life ‐ total score · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ monotherapy: lumacaftor vs placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 85 participants
Low

Summary of findings ‐ monotherapy: lumacaftor vs placebo

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ monotherapy: lumacaftor vs placebo

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 61 participants
Moderate